• Entecavir (BMS200475): Mechanistic Precision in HBV Inhibiti

  2026-04-20

  Entecavir (BMS200475) is a potent, selective inhibitor of HBV DNA polymerase, effective in chronic hepatitis B infection therapy. This article details its molecular action, clinical benchmarks, and protocol parameters, referencing APExBIO's BA1816 product and current peer-reviewed evidence.

• IWR-1-endo (SKU B2306): Reliable Wnt Signaling Inhibition in

  2026-04-20

  This article addresses key laboratory challenges in cell viability and proliferation assays where Wnt/β-catenin pathway modulation is critical. Scenario-driven Q&A blocks demonstrate how IWR-1-endo (SKU B2306) offers reproducible, data-backed solutions for colorectal cancer research and stem cell studies, supporting rigorous experimental outcomes.

• Balsalazide Disodium: Protocols for Inflammation Research

  2026-04-19

  Balsalazide Disodium Dihydrate is transforming inflammation research with its targeted, colon-specific activation. This article unpacks experimental workflows, radiotracer imaging protocols, and troubleshooting tips, enabling precise modeling of ulcerative colitis and immune signaling pathways.

• APEX2 Proximity Labeling Maps RAB GTPase Networks and Functi

  2026-04-18

  This study leverages APEX2-based proximity labeling to systematically map the protein interaction networks of 23 human RAB GTPases, uncovering novel roles for RAB14 in EARP complex and UHRF1BP1 endosomal recruitment. The findings advance our understanding of RAB-mediated membrane trafficking and provide a proteomic resource for further cell biology research.

• Sodium dicloxacillin monohydrate: Optimizing MSSA Infection

  2026-04-17

  Sodium dicloxacillin monohydrate stands out as a targeted, reproducible tool for MSSA and Gram-positive bacterial infection research. Its precise inhibition of penicillin-binding proteins, tunable efficacy across physiological and acidic pH, and robust in vitro/in vivo benchmarks make it indispensable for preclinical workflows. Discover advanced troubleshooting, protocol optimization, and how APExBIO’s product delivers data-driven reliability.

• Jiao-tai-wan Modulates SIRT1 to Restore Ovarian Steroidogene

  2026-04-16

  This study uncovers how the herbal formula Jiao-tai-wan and its active component coptisine attenuate polycystic ovary syndrome (PCOS) by suppressing SIRT1 ubiquitination, thereby restoring mitochondrial cholesterol import and normal ovarian steroidogenesis. These findings clarify a previously uncharacterized molecular pathway and suggest novel research directions for targeted intervention in PCOS models.

• YAP-TEAD Regulation of Super-Enhancers in Ectoderm Commitmen

  2026-04-15

  Wang et al. reveal how the YAP-TEAD transcriptional module orchestrates super-enhancer (SE) networks, directing early surface ectoderm commitment from pluripotent stem cells. This integrative study illuminates the chromatin and regulatory logic behind epithelial lineage specification, with implications for regenerative medicine and cell therapy design.

• SMYD2 Inhibition Reduces RCC Progression and Drug Resistance

  2026-04-14

  This study uncovers the oncogenic role of SMYD2 in clear cell renal cell carcinoma (ccRCC), showing that its inhibition downregulates miR-125b and sensitizes tumors to chemotherapeutics by suppressing P-glycoprotein-mediated multidrug resistance. These findings suggest new prognostic and therapeutic avenues for overcoming chemoresistance in RCC.

• Ridaforolimus (Deforolimus): mTOR Inhibition and Senescence

  2026-04-13

  Explore Ridaforolimus (Deforolimus, MK-8669) as a next-generation mTOR inhibitor with distinct anti-proliferative and anti-angiogenic properties. This article reveals unique insights into senescence-targeted research, protocol optimization, and advances beyond existing workflows.

• Tetraethylammonium Chloride: Beyond K+ Blockade—A Translatio

  2026-04-12

  Discover the multifaceted role of tetraethylammonium chloride (TEAC) in vascular and metabolic research. This article uniquely bridges ion channel pharmacology with translational implications for ganglionic transmission and disease modeling.

• Vitamin C in Organoid Models: Bridging Cancer and Antiviral

  2026-04-12

  This thought-leadership article explores how high-purity Vitamin C (ascorbic acid) is poised to transform translational research at the intersection of cancer biology and antiviral drug discovery. Drawing on mechanistic insights, rigorous validation in organoid models, and the latest hepatitis E virus (HEV) breakthroughs, we detail strategic guidance for leveraging Vitamin C as an anticancer agent and apoptosis inducer. This piece uniquely contextualizes APExBIO’s Vitamin C within advanced organoid workflows, differentiates from standard product pages, and establishes a new benchmark for experimental rigor in precision oncology and infectious disease research.

• 2-Deoxy-D-glucose: Precision Glycolysis Inhibition in Cancer

  2026-04-11

  Harness 2-Deoxy-D-glucose (2-DG) as a versatile tool to dissect glycolytic flux, optimize KIT-positive tumor and viral inhibition workflows, and induce metabolic oxidative stress with high reproducibility. This article guides you through robust experimental protocols, integrates recent breakthroughs in glucose metabolism, and delivers actionable troubleshooting insights for maximizing data quality.

• Rottlerin as a PKC Inhibitor: Advanced Workflows & Solutions

  2026-04-11

  Rottlerin’s unique selectivity as a PKCδ inhibitor enables precise dissection of signaling pathways in cancer, apoptosis, and virology research. Explore evidence-based workflows, real-world troubleshooting, and strategic protocol enhancements that set Rottlerin (APExBIO, SKU B6803) apart from conventional kinase inhibitors.

• Redefining CB1 Antagonism: AM 281 and the Future of Neuro...

  2026-04-10

  This thought-leadership article unpacks the mechanistic and translational promise of AM 281—a selective CB1 receptor antagonist and inverse agonist—for advancing neuropharmacology research in memory impairment, addiction, and neurodegenerative models. Drawing on recent insights into the CB1-CREB-GLT-1 signaling axis and integrating experimental best practices, we guide translational researchers on leveraging AM 281 for robust, next-generation investigations. This piece goes beyond conventional product pages by synthesizing state-of-the-art evidence, competitive positioning, and visionary strategies for the cannabinoid receptor field.

• AM 281: Unlocking Selective CB1 Antagonism for Advanced N...

  2026-04-09

  Explore the scientific foundations and unique translational potential of AM 281, a selective CB1 cannabinoid receptor antagonist, in neuropharmacology. This article delves into its molecular mechanisms, cognitive dysfunction models, and novel research applications beyond existing reviews.

407 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page